Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention  Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 34, 2521-2529, October 1, 1974]
© 1974 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Eckner, R. J.
Right arrow Articles by Dmochowski, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Eckner, R. J.
Right arrow Articles by Dmochowski, L.

Studies on the Biological and Antigenic Properties of ESP-1 Type C Virus Particles1

R. J. Eckner, E. S. Priori, E. A. Mirand2 and L. Dmochowski

Department of Biological Resources, Roswell Park Memorial Institute, Buffalo, New York 14203 [R. J. E., E. A. M.], and Department of Virology, The University of Texas System Cancer Center, M. D. Anderson Hospital and Tumor Institute, Houston, Texas 77025 [E. S. P., L. D.]

ESP-1 virus provides a helper function to defective Friend spleen focus-forming virus (SFFV). This helper activity is demonstrable only in B-type mice (Fv-1bb) under conditions in which the N-tropic lymphatic leukemia-inducing virus contained in the Friend virus complex is inhibited. ESP-1 virus therefore expresses a B-tropic host range in vivo with respect to its ability to provide a helper function to defective SFFV. Further, this helper activity is directly associated with the presence of the ESP-1 virus since activity was recovered only from gradient samples ranging from 1.15 to 1.17 g/ml. All samples contained ESP-1 virus and Mycoplasma. However, Mycoplasma derived from the ESP-1 cell line and maintained in broth culture only enhanced SFFV titer estimates and failed to provide a helper function to SFFV. ESP-1 virus helper activity is dose dependent and heat labile and is neutralized by rat antiserum directed against both whole and Tween:etherdisrupted ESP-1 virus. Further, ESP-1 virus is not neutralized by type-specific murine antiserum directed against both the Rauscher virus complex and the lymphatic leukemia-inducing helper virus component of the Rauscher virus complex and Moloney leukemia virus. These findings, together with the observations that these same murine antisera neutralized human-embryo-kidney-cell-grown Rauscher leukemia virus, suggest that the type C virus designated ESP-1 has some of the biological properties of the murine leukemia viruses (i.e., helper activity for the induction of leukemia in mice) but does not contain type-specific envelope antigen(s) characteristic of Moloney leukemia virus, N-tropic Friend lymphatic leukemia-inducing virus, or human-embryo-kidney-cell-grown Rauscher leukemia virus.

1 Supported in part by Contract 1 CP 33304 within the Virus Cancer Program of the National Cancer Institute, Bethesda, Md., and by American Cancer Society Grant VC-82.

2 To whom reprint requests should be addressed, at Roswell Park Memorial Institute, 666 Elm Street, Buffalo, N. Y. 14203.

Received 4/16/74. Accepted 5/31/74.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1974 by the American Association for Cancer Research.